Need help finding what you are looking for?
Contact Us
PUBLISHER: Transparency Market Research | PRODUCT CODE: 1487557
PUBLISHER: Transparency Market Research | PRODUCT CODE: 1487557
Companion Diagnostic Tests in Oncology Market (Detection Technique: Protein Detection, DNA Detection, and Others; and Biomarker: EGFR, KRAS, HER2, BRAF V600E, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
PUBLISHED:
PAGES: 232 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Companion Diagnostic Tests in Oncology Market - Scope of Report
TMR's report on the global companion diagnostic tests in oncology market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global companion diagnostic tests in oncology market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global companion diagnostic tests in oncology market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the companion diagnostic tests in oncology market.
| Market Snapshot | |
|---|---|
| Market Value in 2023 | US$ 6.1 Bn |
| Market Value in 2034 | US$ 17 Bn |
| CAGR | 9.5% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global companion diagnostic tests in oncology market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global companion diagnostic tests in oncology market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global companion diagnostic tests in oncology market.
The report delves into the competitive landscape of the global companion diagnostic tests in oncology market. Key players operating in the global companion diagnostic tests in oncology market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global companion diagnostic tests in oncology market profiled in this report.
Key Questions Answered in Global companion diagnostic tests in oncology Market Report:
- What is the sales/revenue generated by companion diagnostic tests in oncology across all regions during the forecast period?
- What are the opportunities in the global companion diagnostic tests in oncology market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2034?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Companion Diagnostic Tests in Oncology Market - Research Objectives and Research Approach
The comprehensive report on the global companion diagnostic tests in oncology market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global companion diagnostic tests in oncology market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global companion diagnostic tests in oncology market.
Product Code: TMRGL4684
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Companion Diagnostic Tests in Oncology Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, 2020 - 2034
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Product/Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
6. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Detection Technique
- 6.1. Introduction and Definitions
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Detection Technique, 2020 - 2034
- 6.3.1. Protein Detection
- 6.3.1.1. Immunohistochemistry
- 6.3.2. DNA Detection
- 6.3.2.1. Polymerase Chain Reaction (PCR)
- 6.3.2.2. Next-generation Sequencing (NGS)
- 6.3.2.3. In Situ Hybridization
- 6.3.3. Others
- 6.3.1. Protein Detection
- 6.4. Market Attractiveness, by Detection Technique
7. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Biomarker
- 7.1. Introduction and Definitions
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Biomarker, 2020 - 2034
- 7.3.1. EGFR
- 7.3.2. KRAS
- 7.3.3. HER2
- 7.3.4. BRAF V600E
- 7.3.5. Others
- 7.3.6. 7.4 Market Attractiveness, by Biomarker
8. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Cancer Type
- 8.1. Introduction and Definitions
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Cancer Type, 2020 - 2034
- 8.3.1. Breast Cancer
- 8.3.2. Lung Cancer
- 8.3.3. Colorectal Cancer
- 8.3.4. Liver Cancer
- 8.3.5. Melanoma
- 8.3.6. Others
- 8.4. Market Attractiveness, by Cancer Type
9. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by End-user
- 9.1. Introduction and Definitions
- 9.2. Key Findings/Developments
- 9.3. Market Value Forecast, by End-user, 2020 - 2034
- 9.3.1. Hospitals
- 9.3.2. Specialty Clinics
- 9.3.3. Diagnostic Labs
- 9.3.4. Others
- 9.4. Market Attractiveness, by End-user
10. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Region
- 10.1. Key Findings
- 10.2. Market Value Forecast, by Region, 2020 - 2034
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
- 10.3. Market Attractiveness, by Region
11. North America Companion Diagnostic Tests in Oncology Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast, by Detection Technique, 2020 - 2034
- 11.2.1. Protein Detection
- 11.2.1.1. Immunohistochemistry
- 11.2.2. DNA Detection
- 11.2.2.1. Polymerase Chain Reaction (PCR)
- 11.2.2.2. Next-generation Sequencing (NGS)
- 11.2.2.3. In Situ Hybridization
- 11.2.3. Others
- 11.2.1. Protein Detection
- 11.3. Market Attractiveness, by Detection Technique
- 11.4. Market Value Forecast, by Biomarker, 2020 - 2034
- 11.4.1. EGFR
- 11.4.2. KRAS
- 11.4.3. HER2
- 11.4.4. BRAF V600E
- 11.4.5. Others
- 11.5. Market Attractiveness, by Biomarker
- 11.6. Market Value Forecast, by Cancer Type, 2020 - 2034
- 11.6.1. Breast Cancer
- 11.6.2. Lung Cancer
- 11.6.3. Colorectal Cancer
- 11.6.4. Liver Cancer
- 11.6.5. Melanoma
- 11.6.6. Others
- 11.7. Market Attractiveness, by Cancer Type
- 11.8. Market Value Forecast, by End-user, 2020 - 2034
- 11.8.1. Hospitals
- 11.8.2. Specialty Clinics
- 11.8.3. Diagnostic Labs
- 11.8.4. Others
- 11.9. Market Attractiveness, by End-user
- 11.10. Market Value Forecast, by Country, 2020 - 2034
- 11.10.1. U.S.
- 11.10.2. Canada
- 11.11. Market Attractiveness Analysis
- 11.11.1. By Detection Technique
- 11.11.2. By Biomarker
- 11.11.3. By Cancer Type
- 11.11.4. By End-user
- 11.11.5. By Country
12. Europe Companion Diagnostic Tests in Oncology Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Detection Technique, 2020 - 2034
- 12.2.1. Protein Detection
- 12.2.1.1. Immunohistochemistry
- 12.2.2. DNA Detection
- 12.2.2.1. Polymerase Chain Reaction (PCR)
- 12.2.2.2. Next-generation Sequencing (NGS)
- 12.2.2.3. In Situ Hybridization
- 12.2.3. Others
- 12.2.1. Protein Detection
- 12.3. Market Attractiveness, by Detection Technique
- 12.4. Market Value Forecast, by Biomarker, 2020 - 2034
- 12.4.1. EGFR
- 12.4.2. KRAS
- 12.4.3. HER2
- 12.4.4. BRAF V600E
- 12.4.5. Others
- 12.5. Market Attractiveness, by Biomarker
- 12.6. Market Value Forecast, by Cancer Type, 2020 - 2034
- 12.6.1. Breast Cancer
- 12.6.2. Lung Cancer
- 12.6.3. Colorectal Cancer
- 12.6.4. Liver Cancer
- 12.6.5. Melanoma
- 12.6.6. Others
- 12.7. Market Attractiveness, by Cancer Type
- 12.8. Market Value Forecast, by End-user, 2020 - 2034
- 12.8.1. Hospitals
- 12.8.2. Specialty Clinics
- 12.8.3. Diagnostic Labs
- 12.8.4. Others
- 12.9. Market Attractiveness, by End-user
- 12.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
- 12.10.1. Germany
- 12.10.2. U.K.
- 12.10.3. France
- 12.10.4. Italy
- 12.10.5. Spain
- 12.10.6. Rest of Europe
- 12.11. Market Attractiveness Analysis
- 12.11.1. By Detection Technique
- 12.11.2. By Biomarker
- 12.11.3. By Cancer Type
- 12.11.4. By End-user
- 12.11.5. By Country/Sub-region
13. Asia Pacific Companion Diagnostic Tests in Oncology Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Detection Technique, 2020 - 2034
- 13.2.1. Protein Detection
- 13.2.1.1. Immunohistochemistry
- 13.2.2. DNA Detection
- 13.2.2.1. Polymerase Chain Reaction (PCR)
- 13.2.2.2. Next-generation Sequencing (NGS)
- 13.2.2.3. In Situ Hybridization
- 13.2.3. Others
- 13.2.1. Protein Detection
- 13.3. Market Attractiveness, by Detection Technique
- 13.4. Market Value Forecast, by Biomarker, 2020 - 2034
- 13.4.1. EGFR
- 13.4.2. KRAS
- 13.4.3. HER2
- 13.4.4. BRAF V600E
- 13.4.5. Others
- 13.5. Market Attractiveness, by Biomarker
- 13.6. Market Value Forecast, by Cancer Type, 2020 - 2034
- 13.6.1. Breast Cancer
- 13.6.2. Lung Cancer
- 13.6.3. Colorectal Cancer
- 13.6.4. Liver Cancer
- 13.6.5. Melanoma
- 13.6.6. Others
- 13.7. Market Attractiveness, by Cancer Type
- 13.8. Market Value Forecast, by End-user, 2020 - 2034
- 13.8.1. Hospitals
- 13.8.2. Specialty Clinics
- 13.8.3. Diagnostic Labs
- 13.8.4. Others
- 13.9. Market Attractiveness, by End-user
- 13.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
- 13.10.1. China
- 13.10.2. Japan
- 13.10.3. India
- 13.10.4. Australia & New Zealand
- 13.10.5. Rest of Asia Pacific
- 13.11. Market Attractiveness Analysis
- 13.11.1. By Detection Technique
- 13.11.2. By Biomarker
- 13.11.3. By Cancer Type
- 13.11.4. By End-user
- 13.11.5. By Country/Sub-region
14. Latin America Companion Diagnostic Tests in Oncology Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast, by Detection Technique, 2020 - 2034
- 14.2.1. Protein Detection
- 14.2.1.1. Immunohistochemistry
- 14.2.2. DNA Detection
- 14.2.2.1. Polymerase Chain Reaction (PCR)
- 14.2.2.2. Next-generation Sequencing (NGS)
- 14.2.2.3. In Situ Hybridization
- 14.2.3. Others
- 14.2.1. Protein Detection
- 14.3. Market Attractiveness, by Detection Technique
- 14.4. Market Value Forecast, by Biomarker, 2020 - 2034
- 14.4.1. EGFR
- 14.4.2. KRAS
- 14.4.3. HER2
- 14.4.4. BRAF V600E
- 14.4.5. Others
- 14.5. Market Attractiveness, by Biomarker
- 14.6. Market Value Forecast, by Cancer Type, 2020 - 2034
- 14.6.1. Breast Cancer
- 14.6.2. Lung Cancer
- 14.6.3. Colorectal Cancer
- 14.6.4. Liver Cancer
- 14.6.5. Melanoma
- 14.6.6. Others
- 14.7. Market Attractiveness, by Cancer Type
- 14.8. Market Value Forecast, by End-user, 2020 - 2034
- 14.8.1. Hospitals
- 14.8.2. Specialty Clinics
- 14.8.3. Diagnostic Labs
- 14.8.4. Others
- 14.9. Market Attractiveness, by End-user
- 14.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
- 14.10.1. Brazil
- 14.10.2. Mexico
- 14.10.3. Rest of Latin America
- 14.11. Market Attractiveness Analysis
- 14.11.1. By Detection Technique
- 14.11.2. By Biomarker
- 14.11.3. By Cancer Type
- 14.11.4. By End-user
- 14.11.5. By Country/Sub-region
15. Middle East & Africa Companion Diagnostic Tests in Oncology Market Analysis and Forecast
- 15.1. Introduction
- 15.1.1. Key Findings
- 15.2. Market Value Forecast, by Detection Technique, 2020 - 2034
- 15.2.1. Protein Detection
- 15.2.1.1. Immunohistochemistry
- 15.2.2. DNA Detection
- 15.2.2.1. Polymerase Chain Reaction (PCR)
- 15.2.2.2. Next-generation Sequencing (NGS)
- 15.2.2.3. In Situ Hybridization
- 15.2.3. Others
- 15.2.1. Protein Detection
- 15.3. Market Attractiveness, by Detection Technique
- 15.4. Market Value Forecast, by Biomarker, 2020 - 2034
- 15.4.1. EGFR
- 15.4.2. KRAS
- 15.4.3. HER2
- 15.4.4. BRAF V600E
- 15.4.5. Others
- 15.5. Market Attractiveness, by Biomarker
- 15.6. Market Value Forecast, by Cancer Type, 2020 - 2034
- 15.6.1. Breast Cancer
- 15.6.2. Lung Cancer
- 15.6.3. Colorectal Cancer
- 15.6.4. Liver Cancer
- 15.6.5. Melanoma
- 15.6.6. Others
- 15.7. Market Attractiveness, by Cancer Type
- 15.8. Market Value Forecast, by End-user, 2020 - 2034
- 15.8.1. Hospitals
- 15.8.2. Specialty Clinics
- 15.8.3. Diagnostic Labs
- 15.8.4. Others
- 15.9. Market Attractiveness, by End-user
- 15.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
- 15.10.1. GCC Countries
- 15.10.2. South Africa
- 15.10.3. Rest of Middle East & Africa
- 15.11. Market Attractiveness Analysis
- 15.11.1. By Detection Technique
- 15.11.2. By Biomarker
- 15.11.3. By Cancer Type
- 15.11.4. By End-user
- 15.11.5. By Country/Sub-region
16. Competition Landscape
- 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
- 16.2. Market Share Analysis, by Company (2023)
- 16.3. Company Profiles
- 16.3.1. Abbott
- 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.1.2. Product Portfolio
- 16.3.1.3. Financial Overview
- 16.3.1.4. SWOT Analysis
- 16.3.1.5. Strategic Overview
- 16.3.2. F. Hoffmann-LA Roche AG
- 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.2.2. Product Portfolio
- 16.3.2.3. Financial Overview
- 16.3.2.4. SWOT Analysis
- 16.3.2.5. Strategic Overview
- 16.3.3. Genomic Health, Inc.
- 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.3.2. Product Portfolio
- 16.3.3.3. Financial Overview
- 16.3.3.4. SWOT Analysis
- 16.3.3.5. Strategic Overview
- 16.3.4. QIAGEN
- 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.4.2. Product Portfolio
- 16.3.4.3. Financial Overview
- 16.3.4.4. SWOT Analysis
- 16.3.4.5. Strategic Overview
- 16.3.5. Agilent Technologies, Inc.
- 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.5.2. Product Portfolio
- 16.3.5.3. Financial Overview
- 16.3.5.4. SWOT Analysis
- 16.3.5.5. Strategic Overview
- 16.3.6. AGENDIA N.V.
- 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.6.2. Product Portfolio
- 16.3.6.3. Financial Overview
- 16.3.6.4. SWOT Analysis
- 16.3.6.5. Strategic Overview
- 16.3.7. bioMerieux SA
- 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.7.2. Product Portfolio
- 16.3.7.3. Financial Overview
- 16.3.7.4. SWOT Analysis
- 16.3.7.5. Strategic Overview
- 16.3.8. Illumina, Inc.
- 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.8.2. Product Portfolio
- 16.3.8.3. Financial Overview
- 16.3.8.4. SWOT Analysis
- 16.3.8.5. Strategic Overview
- 16.3.9. Siemens Healthineers
- 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.9.2. Product Portfolio
- 16.3.9.3. Financial Overview
- 16.3.9.4. SWOT Analysis
- 16.3.9.5. Strategic Overview
- 16.3.10. Thermo Fisher Scientific Inc.
- 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.10.2. Product Portfolio
- 16.3.10.3. Financial Overview
- 16.3.10.4. SWOT Analysis
- 16.3.10.5. Strategic Overview
- 16.3.11. BioGenex
- 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.11.2. Product Portfolio
- 16.3.11.3. Financial Overview
- 16.3.11.4. SWOT Analysis
- 16.3.11.5. Strategic Overview
- 16.3.1. Abbott
Product Code: TMRGL4684
List of Tables
- Table 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
- Table 02: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
- Table 03: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
- Table 04: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
- Table 05: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Region, 2020 - 2034
- Table 06: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country, 2020 - 2034
- Table 07: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
- Table 08: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
- Table 9: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
- Table 10: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
- Table 11: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
- Table 12: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
- Table 13: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
- Table 14: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
- Table 15: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
- Table 16: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
- Table 17: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
- Table 18: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
- Table 19: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
- Table 20: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
- Table 21: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
- Table 22: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
- Table 23: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
- Table 24: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
- Table 25: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
- Table 26: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
- Table 27: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
- Table 28: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
- Table 29: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
- Table 30: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
List of Figures
- Figure 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million), by Region, 2023 - 2034
- Figure 02: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Detection Technique, 2023
- Figure 03: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2023
- Figure 04: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Biomarker, 2023
- Figure 05: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2023
- Figure 06: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Cancer Type, 2023
- Figure 07: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2023
- Figure 08: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023
- Figure 09: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023
- Figure 10: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region, 2023
- Figure 11: Global Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast, 2020 - 2034
- Figure 12: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
- Figure 13: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
- Figure 14: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
- Figure 15: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
- Figure 16: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
- Figure 17: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
- Figure 18: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023
- Figure 19: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023
- Figure 20: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Region, 2023 - 2034
- Figure 21: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Region, 2024 - 2034
- Figure 22: North America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
- Figure 23: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country, 2024 - 2034
- Figure 24: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2023 - 2034
- Figure 25: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
- Figure 26: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
- Figure 27: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
- Figure 28: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
- Figure 29: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
- Figure 30: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
- Figure 31: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
- Figure 32: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
- Figure 33: Europe Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
- Figure 34: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
- Figure 35: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
- Figure 36: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
- Figure 37: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
- Figure 38: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
- Figure 39: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
- Figure 40: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
- Figure 41: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
- Figure 42: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
- Figure 43: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
- Figure 44: Asia Pacific Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
- Figure 45: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
- Figure 46: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
- Figure 47: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
- Figure 48: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
- Figure 49: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
- Figure 50: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
- Figure 51: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
- Figure 52: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
- Figure 53: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
- Figure 54: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2023-2034
- Figure 55: Latin America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
- Figure 56: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
- Figure 57: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
- Figure 58: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
- Figure 59: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
- Figure 60: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
- Figure 61: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
- Figure 62: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
- Figure 63: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
- Figure 64: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
- Figure 65: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
- Figure 66: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
- Figure 67: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
- Figure 68: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
- Figure 69: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
- Figure 70: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
- Figure 71: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
- Figure 72: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
- Figure 73: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
- Figure 74: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
- Figure 75: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
- Figure 76: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.